Anti-Viral Therapies Market Expected to Reach $46.2 Billion by 2026—Allied Market Research


quote Surge in global burden of viral infection and stronger pipeline of anti-viral drugs are major factors that drive the growth of the anti-viral therapies market. Furthermore, increase in number of product approvals for combination therapy is expected to boost the market growth in the coming years quote

Onkar Sumant
Manager, Healthcare at Allied Market Research

Get 20% Free Customization In This Report
Follow us on Social Media:       

According to a new report published by Allied Market Research, titled, “Anti-viral Therapies Market by Application, Type, and Mechanism of Action:  Opportunity Analysis and Industry Forecast, 2019-2026,” the global anti-viral therapies market size was valued at $38,316.5 million in 2018, and is projected to reach $46,213.4 million by 2026 registering a CAGR of 2.4% from 2019 to 2026. Antiviral therapies make use of drugs that inhibit the development of the virus causing infection. These drugs do not kill the target pathogen directly. These therapies are mostly particular against viral infections and do not cause side effects in the host’s body. Anti-viral therapies are widely used in treating HIV, herpes, hepatitis, influenza and other viral infections such as chicken pox and papilloma. 

The factors that drive the growth of the market include rise in prevalence of viral infections globally and presence of robust product pipeline with several pharmaceutical giants. Conversely, higher cost for treating these infections and shift in preference of the patients toward homeopathy and naturopathy are some of the key issues expected to hinder the antiviral therapies market growth. On the contrary, R&D for developing combination therapies to effectively eradicate the infections is anticipated to provide lucrative opportunities for the growth of the anti-viral therapies market during the forecast period. 

The global antiviral therapies market is segmented on the basis of application, type, mechanism of action, and region. Based on application, the market is categorized into HIV, hepatitis, herpes, influenza, and other viral diseases. HIV segment was the largest revenue contributor to the anti-viral therapies market in 2018 and is expected to continue this trend during the forecast period, owing to increase in incidences of HIV globally. For instance, as per the data published by UNAIDS, in 2017, around 37 million of the global population is living with HIV. The prevalence of HIV among adults was estimated to be 0.8%. Moreover, increase in consumption of HIV anti-viral drugs for combating infection is major driving factor for the growth of the anti-viral therapies market for HIV segment. On the basis of type, it is classified into generic drugs and branded drugs. The branded drugs segment is a major revenue contributor to the anti-viral therapies market in 2018 and is expected to continue its dominance throughout the forecast period, owing to availability of large number of branded drugs for treating various viral infections. On the basis of mechanism of action, it is divided into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. The nucleotide polymerase inhibitor segment is considered as the most lucrative segment in the anti-viral therapies market, owing to its increasing usage in Hepatitis C infection and are considered to be the first-line treatment for any viral infection. This increase in the usage of nucleotide polymerase inhibitor for treating viral infection is expected to boost the growth of the market during the forecast period. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the global antiviral therapies market in 2018 and is expected to continue its dominance throughout the forecast period, owing to rise inincidences of infectious diseases across the region. Favorable government initiatives undertaken by the U.S. government to combat the prevalence and occurrence of infectious diseases across the North American region are expected to provide ample opportunities for the growth of the anti-viral therapies market in the coming years. Asia-Pacific is expected to grow at the fastest CAGR during the forecast period due to presence of several generic pharmaceutical players and increase in investment for drug development in South Asian countries.

The report provides a comprehensive analysis of the key players operating in the global anti-viral therapies market, which include F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott Laboratories, AstraZeneca plc, AbbVie Inc., Aurobindo Pharma Limited, Johnson & Johnson, and Merck & Co., Inc. The other players in the value chain (companies not included in the report) include Schering-Plough Corporation, Cipla, and Dr Reddy’s.

Key Findings Of The Study

  • Nucleotide polymerase inhibitor segment occupied 38.44% share of the global anti-viral therapies market in 2018.

  • By application, HIV segment is anticipated to grow with the highest CAGR throughout the forecast period.

  • By type, the generic drugs segment accounted for 46.8% share of the market in 2018. 

  • Asia-Pacific is anticipated to grow at the 2.8% during the analysis period. 

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com


For Media Inquiries, Please Contact

Ram D
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at


First time buyer?
Check offers and discount on this report
To get this report

Click Here

quote Anti-Viral Therapies Market by Type (Generic Drugs and Branded Drugs), Application (HIV, Hepatitis, Herpes Virus, Influenza, and Other Applications), and Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others): Global Opportunity Analysis and Industry Forecast, 2019-2026 quote

View Report

Avenue: Entire Library membership of Allied Market Research Reports at your disposal

  • Avenue is an innovative subscription-based online report database.
  • Avail an online access to the entire library of syndicated reports on more than 2,000 niche industries and company profiles on more than 12,000 firms across 11 domains.
  • A cost-effective model tailored for entrepreneurs, investors, and students & researchers at universities.
  • Request customizations, suggest new reports, and avail analyst support as per your requirements.
  • Get an access to the library of reports at any time from any device and anywhere.


Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers


Featured Readings


Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

Get Industry Data Alerts

Buy Full Version
"Anti-Viral Therapies Market"
Purchase Enquiry